What is TORPEDO-CF?
Cystic Fibrosis (CF) patients are at risk of developing infection in their lungs which can cause health problems. Pseudomonas aeruginosa (PsA) is a common cause of infection. New isolations of PsA are treated with antibiotics in an attempt to get rid of the germ. Antibiotics are either given orally (by mouth) or intravenously (by a tube into the vein), both are usually given with inhaled antibiotics via a nebuliser. We know that both treatment types work however nobody knows if one is better than the other.
The TORPEDO-CF study has been designed to compare the two treatments and find out whether there is any difference between them. So far there have not been any studies carried out to test this.
Why is it important to treat PsA?
If PsA gets a foothold in the lungs, it can cause life long, chronic infection. This can lead to worsening symptoms (such as cough), a decline in lung function, more frequent hospital admissions and a deterioration in quality of life. We can get rid of PsA from the lungs but only if we if we treat it early on.
The results of this study can be used to help doctors decide which treatment type should be used to treat new isolations of PsA giving patients the best possible chance of avoiding chronic infection for as long as possible.
Download TORPEDO-CF patient information sheets here
All patients in the TORPEDO have completed the trial.
The final trial protocol can be found below:
Hannah Dourley aged 7 years joined the trial in October 2015.
Hannah said "It's important that I help research to make other children with CF better."
Her mum Vicky said "The trial process was daunting at first but as it turned out, there was nothing to be worried about. We are pleased to be able to help with CF research".
She was randomised to receive intravenous treatment, the photo shows her enjoying her stay on the ward at Salisbury District Hospital.
Read more patient stories here
Progress with Recruitment
In order to answer this important question 280 recruited patients are needed.
We have now achieved over 90% of our recruitment target!
286 patients recruited so far.
See where patients have been recruited here